Sherron Kell, MD, MPH has been appointed senior vice president of Clinical Development at Provention Bio, Inc., a clinical stage biopharmaceutical company. Dr. Kell will lead the PRV-031 (teplizumab) program, including the oversight of the Phase III PROTECT study and clinical support of anticipated regulatory submissions, and will report to Dr. Eleanor Ramos, chief medical and operating officer.

PRV-031 (teplizumab) is an anti-CD3 monoclonal antibody in development for the interception and prevention of clinical type 1 diabetes (T1D).  PRV-031 (teplizumab) has been granted Breakthrough Therapy Designation for the prevention or delay of clinical T1D in individuals at-risk of developing the disease and orphan designation for newly diagnosed T1D.

“The addition of Sherron further enhances our leadership team during a transformational time for Provention,” stated Ashleigh Palmer, chief executive officer of Provention Bio. “Sherron’s expertise and extensive clinical development experience will be invaluable as we execute our clinical and regulatory strategy for PRV-031 (teplizumab) for the interception and prevention of T1D.”

Dr. Kell most recently served as vice president at Impax Pharmaceuticals, now Amneal Pharmaceuticals, overseeing Clinical R&D, Medical Affairs and the Pharmacovigilance and Drug Safety departments across all stages of clinical studies. Previously, she was senior director, Clinical R&D at Johnson & Johnson, and Scientific Director at Novartis Pharmaceuticals.